Patents by Inventor Jose A. Seoane Fernandez

Jose A. Seoane Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treatments Based Upon Molecular Characterization of Breast Cancer
    Publication number: 20220359084
    Abstract: Stratification of risk and methods of treatment based on a breast cancer's molecular profile are provided. Copy number aberrations of various genomic loci and expression levels of various genes are used to molecularly subtype patients and in some instances to determine a breast cancer's aggressiveness and risk of relapse. Breast cancers having a particular molecular subtype with an associated risk of relapse can be stratified and therapeutically targeted.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 10, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Christina Curtis, Jose A. Seoane Fernandez
  • Systems and Methods to Identify Pancreatic Ductal Adenocarcinoma and Uses Thereof
    Publication number: 20220273684
    Abstract: Embodiments herein describe systems and methods to identify and treat pancreatic ductal adenocarcinoma (PDAC) based on cell of origin. Various embodiments comprise assessing transcriptomic data to identify gene expression profiles for the cancer. Based on type of cancer, additional embodiments treat individuals for PDAC. Further embodiments identify possible treatments for a PDAC tumor, by screening effective treatments, including drugs.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 1, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Laura D. Attardi, Christina Curtis, Brittany M. Flowers, Hang Xu, Jose A. Seoane Fernandez
  • Methods of Treatments Based Upon Anthracycline Responsiveness
    Publication number: 20220233563
    Abstract: Methods of treatment based on a neoplasm's responsiveness to anthracycline are provided. Chromatin accessibility or expression levels of chromatin regulatory genes are used in some instances to determine whether a neoplasm will respond to anthracycline treatment. Anthracyclines are utilized to treat various individuals' neoplasms and cancers, as determined by their anthracycline responsiveness.
    Type: Application
    Filed: March 30, 2020
    Publication date: July 28, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerald R. Crabtree, Christina Curtis, Jose A. Seoane Fernandez, Jacob G. Kirkland